Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lexaria Bioscience (LEXX) EBITDA Margin (2017 - 2026)

Lexaria Bioscience's EBITDA Margin history spans 10 years, with the latest figure at 7146.72% for Q1 2026.

  • Quarterly results put EBITDA Margin at 7146.72% for Q1 2026, down 553266.0% from a year ago — trailing twelve months through Feb 2026 was 2572.59% (down 76985.0% YoY), and the annual figure for FY2025 was 1693.15%, down 44064.0%.
  • EBITDA Margin for Q1 2026 was 7146.72% at Lexaria Bioscience, down from 1543.16% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 465.2% in Q1 2024 to a low of 40659.8% in Q3 2022.
  • The 5-year median for EBITDA Margin is 2290.74% (2022), against an average of 5191.81%.
  • The sharpest move saw EBITDA Margin tumbled -4063915bps in 2022, then surged 3662832bps in 2023.
  • Year by year, EBITDA Margin stood at 1796.64% in 2022, then skyrocketed by 57bps to 776.68% in 2023, then tumbled by -89bps to 1471.74% in 2024, then decreased by -5bps to 1543.16% in 2025, then crashed by -363bps to 7146.72% in 2026.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 7146.72%, 1543.16%, and 2156.28% for Q1 2026, Q3 2025, and Q2 2025 respectively.